Samsung Investigates GLP-1 and Muscle Loss
Samsung has launched a clinical study involving 100 adults who are starting GLP-1 medications. The goal is to determine whether data from the Galaxy Watch 8 can help manage muscle loss—a common concern for patients on these drugs. This research builds on a KFF survey showing that nearly one in five U.S. adults has used GLP-1s for type 2 diabetes or weight loss. Scientists are examining long-term treatment effects, particularly the loss of lean muscle mass, which can account for over 30% of total weight lost.
How the Study Works
The Samsung study will collect data from the Galaxy Watch 8 and Samsung Health app to track participants' body composition, physical activity levels, and heart rate. Participants are split into two groups:
- The first group uses the Galaxy Watch 8 for bioelectrical impedance analysis to measure body composition, activity tracking, and personalized guidance.
- The second group receives standard care recommendations.
Results will be compared using medical-grade DXA scans.
“Patients on GLP-1s often experience a decline in muscle mass, which can increase the risk of cardiovascular disease and lower their resting metabolic rate.”
Dr. Melissa Putman
Dr. David Brennan of the Mayo Clinic also emphasized that “one of the major concerns is muscle loss” and that “more than 30% of weight lost during treatment can come from muscle.”
Researchers at the University of Virginia have found that muscle loss can negatively impact health by raising the risk of heart disease. “Continuous data collection from wearable devices could help doctors better assess patient status and adjust treatment more quickly,” added Dr. Putman.
This study is part of Samsung’s broader push into health technology. The company has previously partnered with Stanford University to develop a sleep apnea detection feature and with Chung-Ang University Gwangmyeong Hospital in South Korea to predict fainting episodes. The outcomes of this new research could have significant implications for patients undergoing GLP-1 therapy.
Samsung's investigation may mark an important step in understanding how GLP-1 drugs affect patients' health, particularly changes in body composition. Muscle loss is a serious issue that must be addressed during treatment, as it can impact overall well-being and quality of life. Using wearable technology to monitor physical condition opens new possibilities for doctors to fine-tune therapies and improve patient outcomes.
As Samsung explores the potential of wearable technology in managing muscle loss for GLP-1 patients, it's worth noting that other weight management solutions are also being evaluated. Recent findings indicate that weight loss surgeries may offer significantly better results compared to medications like Ozempic. This comparison highlights the diverse approaches available for those struggling with weight management and the importance of personalized treatment options.